Exclusive: Therapists and Trialists from Lykos’ Phase 3 MDMA-Assisted Therapy Studies Push Back on ICER’s Critical Draft Report Post published:April 29, 2024 Post category:News/Opinions
Natural Medicine Advisory Bulletin 11: March & April 2024 Post published:April 29, 2024 Post category:Colorado Natural Medicine Advisory Bulletin
Pα+ Psychedelic Bulletin #162: EQUULUS Therapeutics Emerges from Stealth; Responses to ICER’s Draft Evidence Report on Lykos’ MDMA; and more… Post published:April 25, 2024 Post category:Psychedelic Bulletin/Pα+
Insights from the European Medicines Agency’s Psychedelics Workshop: A Pα+ Dispatch Post published:April 23, 2024 Post category:Analysis/News/Pα+
Pα+ Psychedelic Bulletin #161: Numinus Shifts Focus to US; Algernon Makes DMT for Stroke Lead Asset; atai Pivots to IV Ibogaine Post published:April 17, 2024 Post category:Psychedelic Bulletin/Pα+
Developing Esketamine (Spravato) and Lessons for Psychedelic Drug Developers with Jaskaran Singh Post published:April 12, 2024 Post category:Interviews/Pα+
Natural Medicine Advisory Bulletin 10.1: Legislative Update Post published:April 9, 2024 Post category:Colorado Natural Medicine Advisory Bulletin
MindMed’s ‘Total Elimination’ of Psychotherapy in LSD Study Stokes Debate Around Its Role in Psychedelic Therapies Post published:April 5, 2024 Post category:Analysis/Pα+
Natural Medicine Advisory Bulletin 10: March 2024 Post published:April 4, 2024 Post category:Colorado Natural Medicine Advisory Bulletin
Senator Kirk Cullimore on Utah’s MDMA and Psilocybin Pilot Program Post published:April 3, 2024 Post category:Interviews